Optimal Timing of BR55 CEUS of the Ovaries

Phase 2

Terminated

• Conditions: Ovarian Cancer
• Interventions: Drug: BR55

• Registration Number: NCT04248153
• Lead Sponsor: Bracco Diagnostics, Inc

Brief Summary

This is an exploratory, single center, open label, prospective study of BR55 to determine the optimal phase of the menstrual cycle for performing BR55 contrast-enhanced ultrasonography (CEUS) of the target ovary in premenopausal women scheduled to undergo preventative surgery because of high familial/hereditary or genetic risk for ovarian cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-10-14
• Study First Submitted: 2020-01-28
• Study First Submitted QC: 2020-01-28
• Study First Posted: 2020-01-30
• Primary Completion: 2020-02-19
• Study Completion: 2021-07-31
• Results First Submitted: 2024-07-11
• Status Verified: 2024-08
• Results First Submitted QC: 2024-08-22
• Last Update Submitted: 2024-08-22
• Results First Posted: 2024-08-23
• Last Update Posted: 2024-08-23

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 3

Inclusion Criteria

Enroll a subject in this study if the subject meets the following inclusion criteria:

• Is a female subject of at least 18 years of age;
• Is premenopausal;
• Is scheduled to undergo preventative salpingo-oophorectomy for high risk of ovarian cancer not earlier than 24 hours and not later than 5 days following the second BR55 CEUS examination;
• Provides written Informed Consent and is willing to comply with protocol requirements.

Exclusion Criteria

Exclude a subject from this study if the subject does not fulfill the inclusion criteria, or if any of the following conditions are observed:

• Is a pregnant or lactating female. Exclude the possibility of pregnancy:

  • by testing on site at the institution (serum βHCG) within 24 hours prior to the start of investigational product administration,
  • by surgical history (e.g., tubal ligation or hysterectomy),

• Has undergone prior systemic therapy for ovarian cancer;

• Has history of concurrent malignancy;

• Has history of any clinically unstable cardiac condition including class III/IV congestive heart failure;

• Has had any severe cardiac rhythm disorders within 7 days prior to enrolment;

• Has severe pulmonary hypertension (pulmonary artery pressure >90mmHg) or uncontrolled systemic hypertension and/or respiratory distress syndrome;

• Has open and/or non-healing wounds in the chest, abdomen and pelvis;

• Has other systemic vascular abnormalities associated with neovascularization that in the opinion of the investigator could significantly affect the ability to evaluate the effects of BR55;

• Is participating in a clinical trial or has participated in another trial with an investigational compound within the past 30 days prior to enrolment;

• Has previously been enrolled in and completed this study;

• Has any known allergy to one or more of the ingredients of the Investigational Product or to any other contrast media;

• Is determined by the Investigator that the subject is clinically unsuitable for the study;

• Has had major surgery, including laparoscopic surgery, within 3 months prior to enrolment;

• Has history of surgery to the ovaries or pelvic inflammatory disease.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group B	BR55	BR55 will be performed in the late follicular phase first and in the early follicular phase thereafter.
Group A	BR55	BR55 will be performed in the early follicular phase first and in the late follicular phase thereafter.

Primary Outcome Measures

Name	Time	Method
Adverse Events	From the time of signing Informed Consent through 24 hours post-dose, up to a maximum of 11 days	Number of participants who received the contrast agent and experienced an adverse event.

Trial Locations

Locations (1)

Stanford University Medical Center; 🇺🇸 Palo Alto, California, United States